1 Hot Biotech Stock + 1 Extremely Strange Call = 10% Plunge

Friday's bad market for Pharmacyclics (NASDAQ: PCYC  ) wasn't the outcome of a poor quarter. In fact, just looking at the 1st quarter sales of Imbruvica, the blood cancer drug it shares with Johnson & Johnson  (NYSE: JNJ  ) , there is no reason to think it won't fulfill its megablockbuster potential. And then management decided to give guidance.

Let this serve as a reminder that the earnings' conference calls are as, if not more, important than the actual numbers. And this is a call whose transcript investors will want to pore over. In what can only be called a bizarre move, management gave a zero growth guidance for Imbruvica sales for the remainder of the year. And then when rightfully questioned, Parmacyclic's management got defensive about their decision asserting they are "not paid for sticking our necks out." But why even give any guidance at all if investors are expecting strong growth and not a "worst-case scenario" that leaves sales flat?

In this episode of Market Checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss Pharmacyclics quarterly results, it's extremely strange earnings call, what they would have done instead, and the implications of this guidance going forward. 

Watch the video below and find out if this hot biotech is cooling off or if it will continue its winning ways.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2944385, ~/Articles/ArticleHandler.aspx, 8/28/2015 3:45:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,584.68 -70.09 -0.42%
S&P 500 1,980.05 -7.61 -0.38%
NASD 4,810.07 -2.63 -0.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 3:30 PM
JNJ $94.72 Down -1.50 -1.56%
Johnson & Johnson CAPS Rating: ****
PCYC $0.00 Down +0.00 +0.00%